SSA
RIGL icon

Sierra Summit Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Sierra Summit Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
31,876
+10,519
+49% +$324K 0.14% 104
2026
Q1 		$577K Sell
21,357
-1,044
-5% -$35.1K 0.08% 150
2025
Q4 		$959K Sell
22,401
-7,785
-26% -$293K 0.15% 95
2025
Q3 		$855K Sell
30,186
-7,083
-19% -$212K 0.13% 116
2025
Q2 		$698K Buy
+37,269
New +$707K 0.12% 119

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sierra Summit Advisors's RIGL Position: Q2 2026 in Review

Sierra Summit Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 49% in Q2 2026, buying an estimated $324K and bringing the position to 31,876 shares worth $1.25M. The position accounts for 0.14% of the portfolio, ranked #104.

Sierra Summit Advisors first reported a position in RIGL in Q2 2025 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Sierra Summit Advisors held 31,876 shares of Rigel Pharmaceuticals worth $1.25M as of Q2 2026.
  • Sierra Summit Advisors bought 10,519 Rigel Pharmaceuticals shares in Q2 2026, an estimated $324K.
  • Rigel Pharmaceuticals made up 0.14% of Sierra Summit Advisors's portfolio in Q2 2026, its #104 holding.
  • Sierra Summit Advisors first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Sierra Summit Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.